Skip to main content
. 2021 Oct 1;12(3):1126–1147. doi: 10.1016/j.apsb.2021.09.025

Figure 3.

Figure 3

Bioinspired membraned coated nanoplatform as nanodecoy in autoimmune diseases therapy. (A) Schematic representation of RBC-ANS neutralizing anti-RBC antibodies in AIHA. (B) RBC-ANS incubated with anti-RBCs demonstrated its particle saturation (250 μg versus 27 μg) and its specific binding capacity. (C) Different concentrations of RBC-ANS coincubated with anti-RBCs illustrated dose-related inhibition of RBC agglutination by RBC-ANS. Reprinted with the permission from Ref. 48. Copyright © 2014, PNAS. (D) Schematic of platelet membrane-coated nanoparticles (PNPs) for the treatment of ITP. (E) In vivo neutralization of anti-platelet antibody activity by PNPs. (F) In vivo treatment of antibody-induced thrombocytopenia by PNPs (n = 8). Reprinted with the permission from Ref. 49. Copyright © 2016, Elsevier. (G) Schematic of RBC-NPs for the targeting of RBC-specific B cells. (H) Targeting of autoimmune B cells using mRBC-NPs. Reprinted with the permission from Ref. 57. Copyright © 2018, American Chemical Society.